1. Courses
  2. Updates of the WHO Classifi...

Updates of the WHO Classification of Brain and Pituitary Tumors



Original release date: June 20, 2024
Access to this course expires on:  May 15, 2027 at 11:59 PM Pacific Time
CME 13.5

Course Description
Capitalizing on the advancement in the molecular diagnostics, the 2021 WHO classification of central nervous system (CNS) tumors recommended substantial changes in taxonomy, nomenclature and grading of CNS tumors. Furthermore, 22 new tumor types/subtypes were introduced and 13 revised terminologies for tumor types/subtypes were implemented. This case-based course will provide a framework for using the contemporary molecular and morphological diagnostic criteria in pediatric and adult brain tumors and pituitary gland neoplasms. Expert faculty will lead sessions to ensure pathologists become familiar with these major changes in diagnostic criteria and utilize them in their daily practice.

This course is a collaboration between the American Association of Neuropathologists and USCAP.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Apply the 2021 CNS WHO taxonomy, nomenclature, grading and classification of adult-type diffuse gliomas.
  • Integrate morphologic and molecular diagnostic techniques to diagnose pediatric-type diffuse low-/high-grade gliomas.
  • Explain the role of integrated molecular diagnosis and histological criteria in the classification of other CNS tumors including ependymal, dural-based, nerve sheath, and CNS embryonal tumors.
  • Summarize the newly described tumor type/subtypes in the 2021 CNS WHO.
  • Apply the 2022 WHO classification of pituitary neuroendocrine tumors (PitNETs) according to cell-lineage and cell type.
  • Discuss the non-neuroendocrine tumors of the sellar region.
  • List the most common nervous system tumors and associated clinical scenarios that should raise suspicion for genetic tumor syndromes.

Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the United States and Canadian Academy of Pathology and the American Association of Neuropathologists. The USCAP is accredited by the ACCME to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 13.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Arie Perry, MD, Sylvia Asa, MD, PhD, Daniel Brat, MD, PhD, Melike Pekmezci, MD

The following IM coordinator reported no relevant financial relationships: Monica Garcia-Buitrago, MD

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.

To earn CME credit, all learners must complete the evaluation. Learners can now self-submit CME on all earned certificates. View and print your certificates by clicking here.

USCAP members receive a discount on all e-Learning courses. Not A Member? Click Here to sign up today.